Redeye provides a research update following the Q4 report published by OncoZenge earlier today.
Fluoguide continued its track record of good cost control in Q4, and reported remaining cash and ST ...
Operationella förutsättningar för en återhämtning är lagda, men marknadsläget försvårar prognostiser...
Profitability (adj. EBIT margin) was better than market consensus (LSEG) expected in Q4.
Group net sales was EUR 29.2m in Q4 (LSEG consensus EUR 28.
Redeye comments on Better Collective’s Q4-results which were slightly ahead of expectations, support...
Redeye updates forecasts on GiG Software after the company’s Q4-report were we have aligned our esti...
Redeye returns with a full update following Medivir’s Q4 report.
Redeye comments on Cheffelo’s decision to fully pass through Sweden’s VAT reduction, noting no P&L i...
As of today, Redeye will place its coverage of Serstech under review until further notice.
Redeye provides a short comment on Fluoguide’s Q4 earnings and the company's outlook for 2026.
Redeye comments on AlzeCure Pharma receiving orphan drug designation (ODD) from the European Medicin...
Botnia Gold redovisade ett starkt fjärde kvartal med intäkter om 118,7 MSEK och EBIT om 45,8 MSEK, d...
Nokian Panimo reports H2’25 figures on Friday. Despite the November profitability guidance cut, we e...
Gofore delivered Q4 EBITA slightly ahead of our and the consensus estimate driven by other operating...
Oriola posted overall good figures in Q4. Net sales and invoicing growth was in the double-digits, a...
Waystream delivered a strong Q4 with 60% y/y sales growth and a return to positive EBITDA, driven pr...
* Strong early efficacy signal * Solid cost management * Fair value range of SEK 0.
HomeMaid redovisade ökad nettoomsättning och EBITA i det fjärde kvartalet.
Nettoomsättningen i Q4’25 uppgick till 149,9 MSEK (116,1), motsvarande en tillväxt om 29,1 %, varav ...
